Answers are grounded in this paper and cite their sources.
// Claudia M. Hattinger 1 , Paola Biason 2 , Erika Iacoboni 1 , Sara Gagno 3 , Marilù Fanelli 1 , Elisa Tavanti 1 , Serena Vella 1 , Stefano Ferrari 4 , Andrea Roli 5 , Rossana Roncato 3 , Luciana Giodini 3 , Katia Scotlandi 1 , Piero Picci 1 , Giuseppe Toffoli 3 , Massimo Serra 1 1 Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Bologna, Italy 2 National Institute of Health and Medical Research (INSERM), Unity 892, University of Medicine of Angers, Angers, France 3 Experimental and Clinical Pharmacology Unit, National Cancer Institute, Aviano, Italy 4 Chemotherapy Ward of Muscoloskeletal Tumours, Orthopaedic Rizzoli Institute, Bologna, Italy 5 Department of Computer Science and Engineering (DISI), University of Bologna, Cesena, Italy Correspondence to: Massimo Serra, email: massimo.serra@ior.it Keywords: osteosarcoma, germline polymorphisms, toxicity, drug response biomarkers, personalized medicine Received: June 01, 2016 Accepted: July 29, 2016 Published: August 22, 2016 ABSTRACT This study aimed to identify associations between germline polymorphisms and risk of high-grade osteosarcoma (HGOS) development, event-free survival (EFS) and toxicity in HGOS patients treated with neo-adjuvant chemotherapy and surgery. Germline polymorphisms of 31 genes known to be relevant for transport or metabolism of all four drugs used in HGOS chemotherapy (methotrexate, doxorubicin, cisplatin and ifosfamide) were genotyped in 196 patients with HGOS and in 470 healthy age and gender-matched controls. Of these 196 HGOS patients, a homogeneously treated group of 126 patients was considered for survival analyses (survival cohort). For 57 of these, treatment-related toxicity data were available (toxicity cohort). Eleven polymorphisms were associated with increased risk of developing HGOS ( p < 0.05). The distribution of polymorphisms in patients was characterized by a higher Shannon entropy. In the survival cohort ( n = 126, median follow-up = 126 months), genotypes of ABCC2_1249A/G, GGH_452T/C, TP53_IVS2+38G/C and CYP2B6*6 were associated with EFS ( p < 0.05). In the toxicity cohort ( n = 57), genotypes of ABCB1_1236T/C, ABCC2_1249A/G, ABCC2_3972A/G, ERCC1_8092T/G, XPD_23591A/G, XRCC3_18067T/C, MTHFR_1298A/C and GGH_16T/C were associated with elevated risk for toxicity development ( p < 0.05). The results obtained in this retrospective study indicate that the aforementioned germline polymorphisms significantly impact on the risk of HGOS development, EFS and the occurrence of chemotherapy-related toxicity. These findings should be prospectively validated with the aim of optimizing and tailoring HGOS treatment in the near future.
No takes yet. Share an insight, caveat, or question.
Hattinger et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: